A Phase II study of nab-paclitaxel and carboplatin chemotherapy plus necitumumab in the first-line treatment of patients with stage IV squamous non-small cell lung cancer

Squamous cell carcinoma, characterized by large keratinizing and atypical polygonal cells in the respiratory bronchial epithelium [1], affects 30% of patients with lung cancer [2]. Historically, patients with squamous NSCLC were treated with first-line platinum-based chemotherapy [3]. Unlike non-squamous NSCLC, there have been no validated, targetable oncogenic drivers to date. The development and recent approval of targeted immunotherapies, either alone or in combination with platinum-doublet chemotherapy based on improved overall survival, offer a new treatment approach for patients with advanced squamous NSCLC.[4,5] However, platinum-based chemotherapy is the preferred treatment option for patients with squamous NSCLC tumors with high tumor proportion scores after disease progression on first-line pembrolizumab monotherapy.[3] In addition, there remains an unmet need for patients with squamous NSCLC who are ineligible for immunotherapy due to pre-existing autoimmunity, solid organ transplant, or prior immune-related toxicity.
Source: Lung Cancer - Category: Cancer & Oncology Authors: Source Type: research

Related Links:

CONCLUSIONS: Simultaneous CRC and CRLM resections seem to be safe when patients are carefully selected, also considering the risk of recurrence concerning oncologic outcomes. The pre-planning of simultaneous resection is mandatory to plan trocar positioning, procedure sequencing, and patient position. PMID: 32490901 [PubMed - in process]
Source: Acta Cirurgica Brasileira - Category: Surgery Authors: Tags: Acta Cir Bras Source Type: research
Publication date: Available online 3 June 2020Source: Carbohydrate PolymersAuthor(s): Ben Newland, Carmine Varricchio, Yvonne Körner, Franziska Hoppe, Christian Taplan, Heike Newland, Dimitri Eigel, Giusy Tornillo, Dagmar Pette, Andrea Brancale, Petra B. Welzel, F. Philipp Seib, Carsten Werner
Source: Carbohydrate Polymers - Category: Biomedical Science Source Type: research
Publication date: Available online 3 June 2020Source: Carbohydrate PolymersAuthor(s): Zhuodong Chai, Chao Teng, Lei Yang, Lianjie Ren, Zhongyue Yuan, Siyuan Xu, Manman Cheng, Yanmei Wang, Zhen Yan, Chao Qin, Xiaopeng Han, Lifang Yin
Source: Carbohydrate Polymers - Category: Biomedical Science Source Type: research
CONCLUSION: a Navigation Program was developed adapted to the Brazilian reality, and attributions of the navigators were created. PMID: 32491120 [PubMed - in process]
Source: Revista Latino-Americana de Enfermagem - Category: Nursing Authors: Tags: Rev Lat Am Enfermagem Source Type: research
Programmed cell death ‐1 immune checkpoint inhibitor (ICI) antibody has proven to be effective in advanced non‐small cell lung cancer (NSCLC) patients positive for programmed cell death‐1 ligand‐1. However, there are currently no reports which evaluate drug efficacy by continuous bronchoscopic observation. A 75‐ year‐old man with complete right atelectasis was diagnosed with squamous cell carcinoma (SCC) of the right lower lobe (tumor proportion score: TPS 90%, cT4N3M0, stage 3C). For first‐line chemotherapy, carboplatin and nab‐paclitaxel were effective for the primary lesion and the right lung atele ctasi...
Source: Thoracic Cancer - Category: Cancer & Oncology Authors: Tags: CASE REPORT Source Type: research
Acetylcholine receptors (AChRs), including nicotinic acetylcholine receptors (nAChRs) and muscarinic acetylcholine receptors (mAChRs), are highly expressed in bronchial epithelial cells. We used The Cancer Genome Atlas (TCGA) data set to evaluate the expression pattern and prognostic value of the AChR gene family in non-small cell lung cancer (NSCLC). The mined data was validated by quantitative real-time polymerase chain reaction (qRT-PCR) and immunohistochemistry (IHC). The survival analysis of TCGA data set showed that only CHRNA7 in the AChR gene family affected prognosis in both lung adenocarcinoma and lung squamous...
Source: Medicine - Category: Internal Medicine Tags: Research Article: Observational Study Source Type: research
Markus Hartl* and Rainer Schneider Center of Molecular Biosciences (CMBI), Institute of Biochemistry, University of Innsbruck, Innsbruck, Austria The neuronal proteins GAP43 (neuromodulin), MARCKS, and BASP1 are highly expressed in the growth cones of nerve cells where they are involved in signal transmission and cytoskeleton organization. Although their primary structures are unrelated, these signaling proteins share several structural properties like fatty acid modification, and the presence of cationic effector domains. GAP43, MARCKS, and BASP1 bind to cell membrane phospholipids, a process reversibly regulate...
Source: Frontiers in Oncology - Category: Cancer & Oncology Source Type: research
Publication date: Available online 13 February 2019Source: The Journal of Molecular DiagnosticsAuthor(s): Amanda Vannitamby, Shona Hendry, Tanvi Makadia, Janine Danks, John Slavin, Louis Irving, Daniel Steinfort, Steven BozinovskiMultiple biomarkers are under evaluation to guide the use of immune checkpoint inhibitors in non–small-cell lung cancer (NSCLC), including programed death ligand 1 (PD-L1) tumor cell staining. We have developed a new approach that accurately quantifies PD-L1 status and identifies multiple mutations by using a single bronchoscopy specimen. A novel molecular marker was identified to detect the...
Source: The Journal of Molecular Diagnostics - Category: Pathology Source Type: research
In conclusion, the existence of EMT-like gene expression in NSMs, may play critical role in tumor progression and be a potential biomarker for prognosis in patients with NSCLC. PMID: 27486775 [PubMed - as supplied by publisher]
Source: Oncotarget - Category: Cancer & Oncology Tags: Oncotarget Source Type: research
Non-small cell lung cancer (NSCLC) is a prevalent and deadly disease because of high incidence and relapse rates. One hypothesis for the high relapse rate is the existence of cancer stem cells (CSCs), a rare subpopulation of cells within these tumors, that are resistant to therapy and thought to be responsible for local and distal recurrence. CSCs are also able to self-renew and differentiate into multiple cell types forming the mass of new tumors. These differentiated progeny that constitute the bulk of the tumor are more sensitive to radiation and chemotherapeutic agents, express tissue of origin markers, and have an int...
Source: Molecular Cancer Research - Category: Cancer & Oncology Authors: Tags: Stem Cell of Origin: Poster Presentations - Proffered Abstracts Source Type: research
More News: Bronchial Tumour | Cancer | Cancer & Oncology | Carcinoma | Chemotherapy | Immunotherapy | Lung Cancer | Lung Transplant | Non-Small Cell Lung Cancer | Respiratory Medicine | Skin Cancer | Squamous Cell Carcinoma | Study | Toxicology | Transplant Surgery | Transplants